<DOC>
	<DOCNO>NCT01118845</DOCNO>
	<brief_summary>The purpose study determine efficacy SyB L-0501 combination rituximab patient relapsed/refractory diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Study SyB L-0501 Combination With Rituximab Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>Primary Objective determine efficacy , measure overall response rate basis Revised Response Criteria Malignant Lymphoma , SyB L-0501 120 mg/m^2/day day2 3 combination rituximab 375 mg/m^2 day 1 21-day cycle patient relapsed/refractory diffuse large B-cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients document Cluster differentiation 20 ( CD20 ) positive lymphoma cell Patients measurable lesion Patients measurable lesion &gt; 1.5 cm major ax Relapsed refractory 1 3 prior therapeutic treatment diffuse large Bcell lymphoma . Patients expect survive least 3 month Patients age 20 75 year time inform consent obtain Performance Status ( P.S . ) 0 1 initial administration study drug Patients adequately maintain organ function Patients capable personally give voluntary informed consent write participate study Patients without treatment le 3 week prior treatment Patients candidate autologous peripheral blood stem cell transplantation discretion investigator . Patients receive adequate prior treatment respond . Patients central nervous system ( CNS ) involvement patient clinical symptom suggestive CNS involvement . Patients serious , active infection Patients serious complication Patients complication medical history serious cardiac disease Patients serious gastrointestinal symptom Patients malignant pleural effusion , cardiac effusion , ascites retention Patients positive hepatitis B surface ( HBs ) antigen , hepatitis C virus ( HCV ) antibody , HIV antibody Patients serious bleed tendency Patients fever 38.0Â°C high Patients , confirm past , interstitial pneumonia , pulmonary fibrosis , pulmonary emphysema Patients active multiple primary cancer patient history malignant cancer within past 5 year , except basal cell cancer skin , squamous cell cancer , cervical cancer situ Patients , confirm past , autoimmune hemolytic anemia Patients receive SyB L0501 past Patients receive cytokine preparation erythropoietin granulocyte colonystimulating factor ( GCSF ) blood transfusion within 2 week examination registration study Patients receive investigational product unapproved medication within 3 month registration study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Lymphoma , Large B-Cell</keyword>
	<keyword>Diffuse , Mantle cell lymphoma , Lymphoma</keyword>
	<keyword>Follicular , Lymphoma</keyword>
	<keyword>Large B-Cell , Diffuse</keyword>
</DOC>